Background
various B-cell malignancies, RCC, CRC
ADVANCED RENAL CELL CARCINOMA, COLORECTAL ADENOCARCINOMA, CHRONIC GRAFT-VERSUS-HOST DISEASE, RCC
Ibrutinib, a first-in-class inhibitor of Bruton’s tyrosine kinase, is approved for the treatment of various B-cell malignancies and chronic graft-versus-host disease. Based on encouraging preclinical data, safety and efficacy of ibrutinib combined with companion drugs for advanced renal cell carcinoma (RCC), gastric/gastroesophageal junctional adenocarcinoma (GC), and colorectal adenocarcinoma (CRC) were evaluated.